HNF4A-AS1 overexpression significantly inhibited the resistance to sorafenib and PUFA supplementation synergistically potentiated this effect, as evidenced by a reduction in tumor volume and a decrease in the liver/body weight ratio (Figure 9G-H). Here, HNF4A is linked to neoplasm.